Versantis,
a Zurich, Switzerland-based clinical-stage biotech company developing
therapies for rare liver and pediatric diseases, closed a CHF16m Series B
financing.
The round was led by Swisscanto Invest by Zürcher Kantonalbank with
participation from Esperante Ventures, investiere, existing investors
Redalpine HealthEquity, and Zürcher Kantonalbank Start-up Finance.
With the closing of this financing round, Dr. Robert Schier, Investment
Director PE/VC Health-Tech at Swisscanto Invest, will join Versantis’
Board of Directors.
The company intends to use the funds to advance clinical development
of novel therapeutics for liver diseases. In particular, the funds will
accelerate the completion of ongoing Phase 1b studies with VS-01 and
advance its clinical development up to clinical proof-of-efficacy (phase
2a) in 2 indications.
Led by Dr. Vincent Forster, CEO and co-founder, and Dr. Meriam
Kabbaj, COO and co-founder, Versantis is a clinical-stage biotech
company focused on the development of orphan drugs in liver diseases and
pediatric inborn errors of metabolism. The company is pursuing
innovative therapies for the acute care of serious liver conditions
based on its proprietary liposomes-based detoxification platform
technology.
Its lead candidate, VS-01, is currently being evaluated in first-in-human clinical trials, with outcomes expected mid-2020.
Source. FinSMEs, September 19, 2019
***
This post was brought to you by Woewoda Communications, your partner in the venture capital, private equity and startup markets; offering strategic communications, public relations & investor relation services to Canadian VCs, PEs, Angels, Endowments/Trusts, Family Offices, and Canadian startups involved in ICT, IoT, blockchain, life sciences, healthcare, agribusiness, clean energy, fintech, AI and robotics.
.
Are you a Canadian GP/LP/CI or a Canadian startup that needs to grow or scale? Give us a call! One of our representatives would love to explain how we vertically design, and then systematically layer each of our communication platforms to effectively reach niche target audiences for our clients. WC offers a unique synergistic approach to effectively communicate our client's message to their target audience.
Serving Vancouver, Montreal, Toronto, Waterloo, Ottawa and Halifax.
No comments:
Post a Comment